# Non-Coding Regulatory Variants in Autoimmune Disease: Biological Mechanisms, Immune Context, and Integrative Multi-Omics Interpretation

## TL;DR

This review explains how non-coding DNA changes contribute to autoimmune diseases by integrating genetic data with immune cell and tissue context using multi-omics and AI.

## Contribution

A step-by-step framework for interpreting non-coding variants in autoimmunity using integrative multi-omics and context-aware analysis.

## Key findings

- Risk variants often act in specific immune cell states or tissue environments.
- Multi-omics and AI improve disease subtyping and drug repurposing potential.
- Functional assays confirm regulatory effects of non-coding variants.

## Abstract

Autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis arise when the immune system attacks the body’s own tissues. Large genetic studies have found many DNA changes linked to these diseases, but most of these changes occur outside genes, in regions that control when and where genes are switched on. Because these “control” regions work differently depending on the immune cell type, its activation state, and the affected tissue, it is often difficult to explain how a risk variant contributes to disease. In this review, we describe a step-by-step approach to interpret non-gene DNA variants in autoimmunity by combining genetic signals with evidence from gene regulation maps, single-cell profiling, and tissue-level spatial studies. We summarize how newer methods can reveal which immune cells and inflammatory conditions expose the effects of risk variants, and how laboratory tests can confirm whether a variant truly changes gene activity. Finally, we explain how combining multiple biological data types with artificial intelligence can help define disease subtypes, improve risk prediction, and suggest drug repurposing opportunities. Together, these strategies support more accurate, mechanism-based understanding of autoimmune disease and can guide precision diagnosis and targeted treatment.

Autoimmune diseases arise from complex interactions between genetic susceptibility, immune regulation, and tissue-specific inflammatory processes, yet most risk variants identified by genome-wide association studies occur in non-coding regions with poorly defined biological functions. This review addresses the challenge of interpreting non-coding regulatory variants in autoimmunity by synthesizing emerging analytical frameworks that integrate functional genomics, single-cell profiling, spatial transcriptomics, and multi-omics data. We describe stepwise strategies that refine statistical associations through regulatory annotation, immune cell–state resolution, and perturbational evidence, highlighting complementary approaches such as massively parallel reporter assays, transcriptome-wide association studies, and single-cell expression quantitative trait locus mapping. These methods demonstrate that many autoimmune risk variants exert context-dependent effects that emerge only in specific immune cell states, activation trajectories, or tissue microenvironments. Advances in spatial and chromatin-informed technologies further clarify how regulatory variation shapes immune circuits in diseases such as systemic lupus erythematosus and rheumatoid arthritis. Finally, we discuss how machine learning-enabled multi-omics integration supports molecular endotyping and therapeutic inference while emphasizing interpretability and reproducibility. Collectively, this review highlights a shift from static variant annotation toward dynamic, context-aware analytical frameworks that enable mechanism-informed interpretation of genetic risk in autoimmune disease.